ProtoKinetix, Inc.: directors' dealings · United States · SEC (Form 4)

About ProtoKinetix, Inc.

ProtoKinetix, Inc. (ticker: PKTX) is a U.S.-listed biotechnology company quoted on the OTC market rather than NYSE/NASDAQ at this stage. Its operating footprint is in the United States, with public business addresses in Ohio, including Dalton and Marietta. The company traces its corporate roots back to 1999, when it was incorporated as RJV Network, Inc.; it adopted the ProtoKinetix name in 2003 and has since repositioned itself around a single scientific platform: AAGP®, a patented anti-aging / anti-freeze glycopeptide designed to support cell survival under stress. From an analyst’s perspective, ProtoKinetix is best described as a research-and-development stage biotechnology and intellectual-property company rather than a commercial drug manufacturer. Its core efforts are concentrated on developing applications for AAGP® in ophthalmology, dermatology, transplant support, regenerative medicine, and selected biomanufacturing use cases. The company’s business model is therefore highly dependent on scientific validation, partner interest, and the ability to convert preclinical or early-stage research into commercially viable products. This creates a classic niche biotech profile: potentially differentiated technology, but with meaningful execution risk, funding reliance, and long development timelines. ProtoKinetix positions AAGP® as its principal asset and repeatedly highlights laboratory testing, toxicity work, and cell-survival research on its corporate website. The molecule is presented as a small, stable compound inspired by natural biological mechanisms associated with animals that survive extreme cold. The company’s published materials indicate that it has been pursuing the platform for many years and has worked with researchers and advisors to broaden potential applications. However, investors should note that the company’s public disclosures still describe it as a development-stage business, which means there is no broad-scale commercial product revenue base to support valuation today. Recent corporate news has also been notable on the governance side. In November 2025, ProtoKinetix announced the death of President and CEO Clarence E. Smith and the appointment of Michael Guzzetta as his successor, alongside continued service as CFO, secretary, and treasurer. For market context, PKTX is not currently a NYSE/NASDAQ listing, which is important when assessing liquidity, disclosure depth, and institutional visibility. Overall, ProtoKinetix is a speculative micro-cap biotech story built around a patented cell-survival molecule, with a long operating history, a focused IP platform, and a development pipeline that remains early and partnership-driven.